AnaptysBio, Inc.
corporate_fare Company Profile
AnaptysBio, Inc. (NASDAQ:ANAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 46 items for ANAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for ANAB spans SCHEDULE 13D/A, 4, 10-Q, 10-KT.
Recent high-impact activity:
- EcoR1's Nodelman Lifts AnaptysBio Stake to 27.8% After $17.2M Buying Run
- EcoR1's Oleg Nodelman Buys $17.2M of AnaptysBio Stock in Three-Day Open-Market Run
- AnaptysBio 10-Q: $3.9M Q3 Income, $153M Cash, GSK Royalty Case Awaits Ruling
- AnaptysBio Swings to $3.9M Q3 Profit on $30.3M Collaboration Revenue
- AnaptysBio Slides 8% as Delaware Hearing Opens in GSK/Tesaro Contract Fight
Financial Snapshot
Short Interest & Short Volume
10.79 days to coverFINRA reported short interest of 5,050,250 shares in ANAB as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 54.1% of ANAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.